Overview

Impact of Hepatic Impairment on the Pharmacokinetics of Deferasirox.

Status:
Completed
Trial end date:
2010-08-01
Target enrollment:
Participant gender:
Summary
This study is to assess the pharmacokinetics of deferasirox in hepatically impaired patients compared to healthy volunteers.
Phase:
Phase 1
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Deferasirox